Hunter Syndrome Mucopolysaccharidosis I and II Drugs Pipeline Review 2014 in New Report Available at ReportsnReports.com

Share Article

ReportsnReports.com adds “Mucopolysaccharidosis I and II (MPS I & II) (Hurler Syndrome) - Pipeline Review, H2 2014” to its store. The report provides an overview of the Mucopolysaccharidosis type I & II (MPS I & II) (Hunter Syndrome) therapeutic pipeline.

Mucopolysaccharidosis I and II Drugs

Mucopolysaccharidosis I and II Drugs

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects.

MPS I is divided into three subtypes based on severity of symptoms. All three types result from an absence of, or insufficient levels of, the enzyme alpha-L-iduronidase. Children born to an MPS I parent carry the defective gene.

Complete report available @ http://www.reportsnreports.com/reports/313331-mucopolysaccharidosis-i-mps-i-hurler-syndrome-pipeline-review-h2-2014.html .

MPS I is the most severe of the MPS I subtypes. Developmental delay is evident by the end of the first year, and patients usually stop developing between ages 2 and 4. This is followed by progressive mental decline and loss of physical skills. Language may be limited due to hearing loss and an enlarged tongue. In time, the clear layers of the cornea become clouded and retinas may begin to degenerate. Carpal tunnel syndrome (or similar compression of nerves elsewhere in the body) and restricted joint movement are common.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Companies Involved in Therapeutics Development:

  •     Athersys, Inc.
  •     OPKO Health, Inc.
  •     Amicus Therapeutics, Inc.
  •     ReGenX Biosciences, LLC
  •     AngioChem Inc.
  •     PTC Therapeutics, Inc.
  •     Fate Therapeutics, Inc.
  •     biOasis Technologies Inc.
  •     ArmaGen Technologies, Inc.

Order a Purchase copy @ http://www.reportsnreports.com/Purchase.aspx?name=313331 .

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects.

MPS II, Hunter syndrome or iduronate sulfatase deficiency, is caused by lack of the enzyme iduronate sulfatase. Hunter syndrome has two clinical subtypes and is the only one of the mucopolysaccharidoses in which the mother alone can pass the defective gene to a son. The incidence of Hunter syndrome is estimated to be 1 in 100,000 to 150,000 male births.

Complete report available @ http://www.reportsnreports.com/reports/313332-mucopolysaccharidosis-ii-mps-ii-hunter-syndrome-pipeline-review-h2-2014.html .

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development:

  •     Lentigen Corporation
  •     Shire Plc
  •     Green Cross Corporation
  •     JCR Pharmaceuticals Co., Ltd.
  •     Fate Therapeutics, Inc.
  •     biOasis Technologies Inc.
  •     ArmaGen Technologies, Inc.

Order a Purchase copy @ http://www.reportsnreports.com/Purchase.aspx?name=313332 .

Scope

  •     The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis I & II (MPS I & II) (Hunter Syndrome)
  •     The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  •     The report reviews key players involved in the therapeutics development for Mucopolysaccharidosis I & II (MPS I & II) (Hunter Syndrome) and enlists all their major and minor projects
  •     The report summarizes all the dormant and discontinued pipeline projects
  •     A review of the Mucopolysaccharidosis I & II (MPS I & II) (Hunter Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  •     Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Reasons to buy

  •     Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  •     Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  •     Develop strategic initiatives by understanding the focus areas of leading companies
  •     Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I & II (MPS I & II) (Hunter Syndrome)
  •     Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  •     Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I & II (MPS I & II) (Hunter Syndrome) pipeline depth and focus of Indication therapeutics
  •     Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
@chinamrreport
Follow >
ReportsnReports
Like >
Follow us on
Visit website